Jacobson Pharma (HKG:2633) expects an increase of over 40% in its profit from continuing operations for the six months ended Sept. 30, compared with the same period last year, a Wednesday Hong Kong bourse filing said.
The pharmaceutical company attributed the projected increase to effective cost control measures, improved results of the company's generic drug business, revenue contributions from newly in-licensed products, and the launch of new products during the reviewing period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments